A Phase III, Extension Clinical Trial to Demonstrate Efficacy and Safety of Liposomal Cyclosprine a Via the PARI Investigational EFlow® Device and SoC in Treating Bronchiolitis Obliterans in Patients Post Single or Double Lung Transplant

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciclosporin (Primary)
Indications Bronchiolitis obliterans
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms BOSTON-3
Sponsors Breath Therapeutics; Zambon SpA

Most Recent Events

27 Jan 2025 Planned End Date changed from 1 Sep 2024 to 1 Dec 2025.
27 Jan 2025 Planned primary completion date changed from 1 Sep 2024 to 1 Dec 2025.
27 Jan 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight